Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 3545914, 8 pages
http://dx.doi.org/10.1155/2016/3545914
Research Article

Lactic Acidosis in Diabetic Population: Is Metformin Implicated? Results of a Matched Case-Control Study Performed on the Type 2 Diabetes Population of Grenoble Hospital University

1Centre Régional de Pharmacovigilance, Pôle Santé Publique, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France
2Service de Biostatistique des Hospices Civils de Lyon, 69002 Lyon, France
3Laboratoire Biostatistique Santé, UCBL, Equipe de l’UMR CNRS 5558, 69495 Pierre-Bénite Cedex, France
4Pôle Pharmacie, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France
5Université Grenoble Alpes, 38000 Grenoble, France

Received 10 December 2015; Revised 15 January 2016; Accepted 8 February 2016

Academic Editor: Mitsuhiko Noda

Copyright © 2016 Marion Lepelley et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Guariguata, D. R. Whiting, I. Hambleton, J. Beagley, U. Linnenkamp, and J. E. Shaw, “Global estimates of diabetes prevalence for 2013 and projections for 2035,” Diabetes Research and Clinical Practice, vol. 103, no. 2, pp. 137–149, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. Haute Autorité de Santé—Stratégie médicamenteuse du contrôle glycémique du diabète de type 2, Août 2015, http://www.has-sante.fr/portail/jcms/c_1022476/fr/strategie-medicamenteuse-du-controle-glycemique-du-diabete-de-type-2.
  3. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetologia, vol. 55, no. 6, pp. 1577–1596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. R. C. Turner, C. A. Cull, V. Frighi, and R. R. Holman, “Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49),” The Journal of the American Medical Association, vol. 281, no. 21, pp. 2005–2012, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-D. Lalau, “Lactic acidosis induced by metformin: incidence, management and prevention,” Drug Safety, vol. 33, no. 9, pp. 727–740, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Biradar, J. L. Moran, S. L. Peake, and J. V. Peter, “Metformin-associated lactic acidosis (MALA): clinical profile and outcomes in patients admitted to the intensive care unit,” Critical Care and Resuscitation, vol. 12, no. 3, pp. 191–195, 2010. View at Google Scholar
  7. S. Salpeter, E. Greyber, G. Pasternak, and E. Salpeter, “Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD002967, 2010. View at Google Scholar · View at Scopus
  8. M. Bodmer, C. Meier, S. Krähenbühl, S. S. Jick, and C. R. Meier, “Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis,” Diabetes Care, vol. 31, no. 11, pp. 2086–2091, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-D. Lalau and J.-M. Race, “Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations,” Drug Safety, vol. 20, no. 4, pp. 377–384, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Vecchio and A. Protti, “Metformin-induced lactic acidosis: no one left behind,” Critical Care, vol. 15, no. 1, article 107, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. I. R. F. van Berlo-van de Laar, C. G. Vermeij, and C. J. Doorenbos, “Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements,” Journal of Clinical Pharmacy and Therapeutics, vol. 36, no. 3, pp. 376–382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. T. A. Chowdhury, R. Wright, and M. M. Yaqoob, “Using metformin in the presence of renal disease,” The British Medical Journal, vol. 350, Article ID h1758, 2015. View at Publisher · View at Google Scholar
  13. A. T. Calabrese, K. C. Coley, S. V. DaPos, D. Swanson, and R. H. Rao, “Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy,” Archives of Internal Medicine, vol. 162, no. 4, pp. 434–437, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. D. T. Eurich, F. A. McAlister, D. F. Blackburn et al., “Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review,” British Medical Journal, vol. 335, no. 7618, pp. 497–501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Papanas, E. Maltezos, and D. P. Mikhailidis, “Metformin and heart failure: never say never again,” Expert Opinion on Pharmacotherapy, vol. 13, no. 1, pp. 1–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. K. P. Vasisht, S.-C. Chen, Y. Peng, and G. L. Bakris, “Limitations of metformin use in patients with kidney disease: are they warranted?” Diabetes, Obesity and Metabolism, vol. 12, no. 12, pp. 1079–1083, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. W. E. Cayley Jr., “Does metformin increase the risk of fatal or nonfatal lactic acidosis?” American Family Physician, vol. 82, no. 9, pp. 1068–1069, 2010. View at Google Scholar · View at Scopus
  18. A. Holstein, D. Nahrwold, S. Hinze, and E.-H. Egberts, “Contra-indications to metformin therapy are largely disregarded,” Diabetic Medicine, vol. 16, no. 8, pp. 692–696, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. R. D. Cohen and H. F. Woods, “Lactic acidosis revisited,” Diabetes, vol. 32, no. 2, pp. 181–191, 1983. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Emslie-Smith, D. I. R. Boyle, J. M. M. Evans, F. Sullivan, and A. D. Morris, “Contraindications to metformin therapy in patients with type 2 diabetes—a population-based study of adherence to prescribing guidelines,” Diabetic Medicine, vol. 18, no. 6, pp. 483–488, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. K. J. Lipska, C. J. Bailey, and S. E. Inzucchi, “Use of metformin in the setting of mild-to-moderate renal insufficiency,” Diabetes Care, vol. 34, no. 6, pp. 1431–1437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Sterner, S. Elmståhl, and A. Frid, “Renal function in a large cohort of metformin treated patients with type 2 diabetes mellitus,” British Journal of Diabetes and Vascular Disease, vol. 12, no. 5, pp. 227–231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. Type 2 Diabetes, 1-Recommendations, Guidance and Guidelines, August 2015, http://www.nice.org.uk/guidance/cg87/chapter/1-recommendations.
  24. T. Scale and J. N. Harvey, “Diabetes, metformin and lactic acidosis,” Clinical Endocrinology, vol. 74, no. 2, pp. 191–196, 2011. View at Google Scholar
  25. C. J. Girman, T. D. Kou, K. Brodovicz et al., “Risk of acute renal failure in patients with Type 2 diabetes mellitus,” Diabetic Medicine, vol. 29, no. 5, pp. 614–621, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. J. K. Duong, T. J. Furlong, D. M. Roberts et al., “The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis,” Drug Safety, vol. 36, no. 9, pp. 733–746, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. InVS—BEH no. 42-43, Diabète traité: quelles évolutions entre 2000 et 2009 en France ?, Disponible sur, 2010, http://www.invs.sante.fr/beh/2010/42_43/.